Designing Issues in Confirmatory Adaptive Population Enrichment Trials

REFERENCES

• ADDPLAN, Inc., an Aptiv Solutions Company. (2012). ADDPLAN PE Version 6.0 User Manual. Cologne, Germany: Aptiv Solutions.
   Google Scholar
• Alosh, M., Huque, M. F. (2009). A flexible strategy for testing subgroups and overall population. Statistics in Medicine 28:3–23.
   PubMed Web of Science ®Google Scholar
• André, T., Boni, C., Navaro, M., Tabernero, J., Hickish, T., Topham, C., Bonetti, A., Clingan, P., Bridgewater, J., Rivero, F., deGramont, A. (2009). Improved overall survival with oxaliplatin, flourouracil, and leucovorin as adjuvant treatment in stage II order III colon cancer in the MOSAIC trial. Journal of Clinical Oncology 27:3109–3116.
   PubMed Web of Science ®Google Scholar
• Barker, A., Sigman, C., Kelloff, G., Hylton, N., Berry, D., Esserman, L. (2009). I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clinical Pharmacology and Therapeutics 86:97–100.
   PubMed Web of Science ®Google Scholar
• Bauer, P., Kieser, M. (1999). Combining different phases in the development of medical treatments within a single trial. Statistics in Medicine 18:1833–1848.
   PubMed Web of Science ®Google Scholar
• Bauer, P., Köhne, K. (1994). Evaluation of experiments with adaptive interim analyses. Biometrics 50:1029–1041.
   PubMed Web of Science ®Google Scholar
• Benda, N., Branson, M., Maurer, W., Friede, T. (2010). Aspects of modernizing drug development using scenario planning and evaluation. Drug Information Journal 44:299–315.
   Web of Science ®Google Scholar
• Brannath, W., Zuber, E., Branson, M., Bretz, F., Gallo, P., Posch, M., Racine-Poon, A. (2009). Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy on oncology. Statistics in Medicine 28:1445–1463.
   PubMed Web of Science ®Google Scholar
• Bretz, F., König, F., Brannath, W., Glimm, E., Posch, M. (2009). Tutorial in biostatistics: Adaptive designs for confirmatory clinical trials. Statistics in Medicine 28:1181–1217.
   PubMed Web of Science ®Google Scholar
• Freidlin, B., Simon, R. (2005). Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clinical Cancer Research 11:7872–7878.
   PubMed Web of Science ®Google Scholar
• Friede, T., Parsons, N., Stallard, N. (2012). A conditional error function approach for subgroup selection in adaptive clinical trials. Statistics in Medicine 31:4309–4320; correction in 32: 2513–2514.
   PubMed Web of Science ®Google Scholar
• Friede, T., Stallard, N. (2008). A comparison of methods for adaptive treatment selection. Biometrical Journal 50:767–781.
   PubMed Web of Science ®Google Scholar
• Hochberg, Y., Tamhane, A. C. (1987). Multiple Comparison Procedures. New York: Wiley.
   Google Scholar
• Jenkins, M., Stone, A., Jennison, C. (2011). An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints. Pharmaceutical Statistics 10:347–356.
   PubMed Web of Science ®Google Scholar
• Kelly, P. J., Stallard, N., Todd, S. (2005). An adaptive group sequential design for phase II/III clinical trials that select a single treatment from several. Journal of Biopharmaceutical Statistics 15:641–658.
   PubMed Web of Science ®Google Scholar
• Lehmacher, W., Wassmer, G. (1999). Adaptive sample size calculations in group sequential trials. Biometrics 55:1286–1290.
   PubMed Web of Science ®Google Scholar
• Maitournam, A., Simon, R. (2005). On the efficiency of targeted clinical trials. Statistics in Medicine 24:329–339.
   PubMed Web of Science ®Google Scholar
• Marcus, R., Peritz, E., Gabriel, K. R. (1976). On closed testing procedures with special reference to ordered analysis of variance. Biometrika 63:655–660.
   Web of Science ®Google Scholar
• Mehta, C., Gao, P. (2011). Population enrichment designs: Case study of a large multinational trial. Journal of Biopharmaceutical Statistics 21:831–845.
   PubMed Web of Science ®Google Scholar
• Mehta, C., Gao, P., Bhatt, D. L., Harrington, R. A., Skerjanec, S., Ware, J. H. (2009). Optimizing trial design: sequential, adaptive, and enrichment strategies. Circulation 119:597–605.
   PubMed Web of Science ®Google Scholar
• NAS-REPORT. (2011). Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. Washington, DC: The National Academies Press.
   Google Scholar
• Parsons, N., Friede, T., Todd, S., Valdes-Marquez, E., Chataway, J., Nicholas, R., Stallard, N. (2012). An R package for implementing simulations for seamless phase II/III clinical trials using early outcomes for treatment selection. Computational Statistics and Data Analysis 56:1150–1160.
   Web of Science ®Google Scholar
• Posch, M., König, F., Branson, M., Brannath, W., Dunger-Baldauf, C., Bauer, P. (2005). Testing and estimating in flexible group sequential designs with adaptive treatment selection. Statistics in Medicine 24:3697–3714.
   PubMed Web of Science ®Google Scholar
• Schoenfeld, D. A. (1983). Sample-size formula for the proportional-hazards regression model. Biometrics 39:499–503.
   PubMed Web of Science ®Google Scholar
• Simon, R. (2004). An agenda for clinical trials in the genomic era. Clinical Trials 1:468–470.
   PubMedGoogle Scholar
• Spiessens, B., Debois, M. (2010). Adjusted significance levels for subgroup analysis in clinical trials. Contemporary Clinical Trials 31:647–656.
   PubMed Web of Science ®Google Scholar
• Stallard, N., Hamborg, T., Parsons, N., Friede, T. (2014). Adaptive designs for confirmatory clinical trials with subgroup selection. Journal of Biopharmaceutical Statistics 24:168–187.
   PubMed Web of Science ®Google Scholar
• Temple, R. (1994). Special study designs: early escape, enrichment, studies in non-responders. Communications in Statistics-Theory and Methods 23:499–531.
   Web of Science ®Google Scholar
• Temple, R. (2005). Enrichment designs: Efficiency in development of cancer treatments. Journal of Clinical Oncology 23:4838–4839.
   PubMed Web of Science ®Google Scholar
• Tournoux-Facon, C., De Ryckee, Y., Tubert-Bitter, P. (2011a). How a new stratified adaptive phase II design could improve targeting population. Statistics in Medicine 30:1555–1562.
   PubMed Web of Science ®Google Scholar
• Tournoux-Facon, C., De Ryckee, Y., Tubert-Bitter, P. (2011b). Targeting population entering phase III trials: a new stratified adaptive phase II design. Statistics in Medicine 30:801–811.
   PubMed Web of Science ®Google Scholar
• Wang, S.-J., Hung, H. M. J., O’Neill, R. T. (2009). Adaptive patient enrichment designs in therapeutic trials. Biometrical Journal 51:358–374.
   PubMed Web of Science ®Google Scholar
• Wang, S.-J., O’Neill, R., Hung, J. (2007). Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharmaceutical Statistics 6:227–244.
   PubMed Web of Science ®Google Scholar
• Wassmer, G. (1999). Multistage adaptive test procedures based on Fisher’s product criterion. Biometrical Journal 41:279–293.
   Web of Science ®Google Scholar
• Wassmer, G. (2006). Planning and analyzing adaptive group sequential survival trials. Biometrical Journal 48:714–729.
   PubMed Web of Science ®Google Scholar
• Wassmer, G. (2011). On sample size determination in multi-armed confirmatory adaptive designs. Journal of Biopharmaceutical Statistics 21:802–817.
   PubMed Web of Science ®Google Scholar